Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
{{output}}
Introduction: Glaucoma affects more than 70 million people worldwide. One of the major therapeutic options for its management is based on the inhibition of the metalloenzyme carbonic anhydrases (CAs, EC 4.2.1.1). CA inhibitors (CAIs) diminish ocular hypertensi... ...
